HEALTHSTORY 768· JULY 10, 2026

Germany moves to more than double drug rebates as U.S. biotech firms retreat into secrecy

The price of selling a branded medicine in Germany may soon rise sharply for drug companies. German lawmakers passed a bill that would increase the mandatory rebate, the fixed discount manufacturers must return to the country's public…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 767Influencer Hero buys Afluencer, adding 17,000-member creator marketplace to its platform NEXT STORY 769 →Clip Strip Corp. corrects its July retailer investment announcement

Keep reading

More from the desk.

29HEALTH

Readers debate doctor credentials, AI in the exam room, and surrogacy in STAT's First Opinion letters

When physician credentials, artificial intelligence in the exam room, and surrogacy generated enough reader mail to warrant a public reply, STAT published the letters. The health and life sciences publ

health1 MIN

50HEALTH

A drug for Angelman syndrome failed its final trial. Researchers say the science is not done.

A late-stage trial for an experimental Angelman syndrome drug came back negative this week, dealing a major blow to patients and to the company behind it. Late-stage, in clinical testing, means the final ro

health2 MIN

55HEALTH

Novartis heart drug pelacarsen fails its largest clinical trial

A closely watched drug for a common heart disease risk factor has failed in its biggest test. Pelacarsen, developed by Novartis, targets Lp(a), a particle made from lipids and proteins whose elevated concentrations in the blood raise the…

health1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk